Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BETUVAKS LIMITED LIABILITY COMPANY has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity involves 1 distinct examiner and 1 distinct art unit. The company's current patent office presence is concentrated in this single matter, reflecting a focused prosecution phase. The involvement of only 1 distinct art unit suggests that the technology being patented is specialized and falls under a specific technical classification within the Biotechnology & Pharmaceuticals field.
GRIZER, CASSANDRA SENN is the busiest examiner, with 1 pending office action. This count of 1 matches the total number of pending office actions for the portfolio. Consequently, the company's immediate prosecution success is tied to the specific feedback and requirements of this one examiner. Because there are no other pending office actions or distinct examiners to consider, the applicant can devote all resources to addressing the single matter currently on file. This lack of examiner diversity means that the applicant's experience is entirely shaped by the 1 distinct examiner, making it vital to understand the specific examination style of GRIZER, CASSANDRA SENN within the context of the 1 distinct art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRIZER, CASSANDRA SENN | 1 | 75.0% | +18.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270390 | Method of Obtaining Betulin as an Adjuvant in a Vaccine Against Coronavirus SARS-COV-2 | GRIZER, CASSANDRA SENN | 32d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270390 | Method of Obtaining Betulin as an Adjuvant in a Vaccine Against Coronavirus SARS-COV-2 | GRIZER, CASSANDRA SENN | 32d overdue |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270390 | Method of Obtaining Betulin as an Adjuvant in a Vaccine Against Coronavirus SARS-COV-2 | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Non-Final OA | 32d overdue | Pending | Jun 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial